Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Matinas BioPharma Holdings Shot Almost 28% Higher Today

By Eric Volkman - Jan 4, 2021 at 7:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The proposed brand name for its leading pipeline drug got an important nod.

What happened

Shares of clinical-stage company Matinas BioPharma Holdings ( MTNB -9.71% ) increased a robust 27.9% on Monday, following news that it won a crucial nod from the Food and Drug Administration.

So what

Matinas said Monday that it received conditional approval from the FDA for the brand name of its leading pipeline drug, MAT9001/Lypdiso. That name has also been accepted via a notice of allowance by the U.S. Patent and Trademark Office, paving the way for Lypdiso to become a registered trademark for the company.

A medical professional using a microscope.

Image source: Getty Images.

Brand names are crucial for biotechs, as they can very effectively stamp a product onto a consumer's memory and dramatically raise product awareness. Some of the better-named products have been hits due to both their effects and branding -- Pfizer's Viagra is one of numerous examples.

Matinas pointed out that a request for proprietary name review and final approval of Lypdiso is going to be included when the company formally submits its new drug application for the medication.

Now what

MAT9001/Lypdiso is an omega-3 fatty acid-based drug that treats cardiovascular disorders. It thus rivals the immensely popular Vascepa from Amarin. Matinas feels its product is superior and "set to become the most effective omega-3 therapy."

This is currently being put to the test in the second of two studies pitting MAT9001 against Vascepa. Data from the study is expected at some point this quarter.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Matinas BioPharma Holdings, Inc. Stock Quote
Matinas BioPharma Holdings, Inc.
MTNB
$0.93 (-9.71%) $0.10
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.27 (2.32%) $1.23
Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$3.57 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.